

QinetiQ Group plc
Total Voting Rights

31 October 2025 - In accordance with the Financial Conduct Authority's (FCA) Disclosure Guidance and Transparency Rule 5.6.1R, QinetiQ Group plc ("the Company") notifies the market that as of 31 October 2025 the Company's issued ordinary share capital consists of 536,526,419 ordinary shares of one penny each. There are no shares held in treasury.

Therefore, the total number of voting rights in the Company is 536,526,419. This figure may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

About QinetiQ:

QinetiQ is an integrated global defence and security company focused on mission-led innovation. QinetiQ employs circa 8,500 highly-skilled people, committed to creating new ways of protecting what matters most; testing technologies, systems, and processes to make sure they meet operational needs; and enabling customers to deploy new and enhanced capabilities with the assurance they will deliver the performance required.

For further information, please contact:

Stephen Lamacraft, Interim Group Investor Relations Director:	+44 (0) 7920 545841
Stephanie Mann, Group Head of Media Relations:	+44 (0) 7770 720268
James Field, Company Secretary:	+44 (0) 7841 662957

QinetiQ Group plc LEI: 213800S8OBDOZMCMUW34

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVRBLBDGIBXDGUB